// App-Quantinova.ai

e20522 : Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.

Researchers

Presenter

  • Sundar Jagannath

Principal Investigators

  • jyotsna mehta

  • Janis Breeze

  • Gabriel Tremblay

  • Lingling Li

  • Noa Biran

  • Sharon Shacham

  • Michael G. Kauffman

  • Jatin J. Shah

Medical Centers

  • Mount Sinai Medical Center, New York, NY

  • Karyopharm Therapeutics, Newton, MA

  • Purple Squirrel Economics, LLC, New York, NY

  • Purple Squirrel Economics, Montreal, QC, Canada

  • Karyopharm Therapeutics, Newton, MA

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

Locations

  • United States

  • Canada

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Selinexor

  • KPT-330

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02336815

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved